Cloning of the class D β-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains

被引:28
作者
Niumsup, P [1 ]
Wuthiekanun, V
机构
[1] Naresuan Univ, Fac Med Sci, Dept Microbiol & Parasitol, Phitsanulok 65000, Thailand
[2] Mahidol Univ, Fac Trop Med, Wellcome Trust Unit, Bangkok 10400, Thailand
关键词
D O I
10.1093/jac/dkf165
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ceftazidime is the antibiotic of choice for the treatment of melioidosis. Ceftazidime-resistant Burkholderia pseudomallei have been identified and beta-lactamase production implicated in resistance. In this study, 25 strains of B. pseudomallei (15 clinical and 10 environmental strains) were examined for their ability to yield mutants that overexpress beta-lactamase. Ceftazidime-resistant mutants were selected readily at high frequency and displayed four- to eight-fold increases in the MICs of ceftazidime. beta-Lactamase activities in both parent and mutant B. pseudomallei strains were examined by a spectrophotometric method. Twelve mutants (48%) showed approximately two- to 31-fold higher ceftazidimase activity compared with their parent strains and 10 (40%) demonstrated more than two-fold increases in imipenemase activity. A class D beta-lactamase gene from B. pseudomallei was cloned and sequenced. The encoded enzyme is an oxacillinase and is homologous to oxacillinases from Ralstonia pickettii and members of the genus Aeromonas. Reverse transcriptase PCR showed that transcription of the class D beta-lactamase gene is increased in ceftazidime-resistant mutants.
引用
收藏
页码:445 / 455
页数:11
相关论文
共 33 条
  • [1] Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii
    Afzal-Shah, M
    Woodford, N
    Livermore, DM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) : 583 - 588
  • [2] ARNOFF SC, 1988, PEDIAT PULMONOLOGY, V4, P72
  • [3] Aeromonas hydrophila AmpH and CepH β-lactamases:: derepressed expression in mutants of Escherichia coli lacking creB
    Avison, MB
    Niumsup, P
    Walsh, TR
    Bennett, PM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) : 695 - 702
  • [4] Differential regulation of L1 and L2 β-lactamase expression in Stenotrophomonas maltophilia
    Avison, MB
    Higgins, CS
    Ford, PJ
    von Heldreich, CJ
    Walsh, TR
    Bennett, PM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) : 387 - 389
  • [5] BAXTER IA, 1994, FEMS MICROBIOL LETT, V122, P251, DOI 10.1016/0378-1097(94)00331-9
  • [6] OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain
    Bou, G
    Oliver, A
    Martínez-Beltran, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) : 1556 - 1561
  • [7] DEVELOPMENT OF RESISTANCE TO CEFTAZIDIME AND CO-AMOXICLAV IN PSEUDOMONAS-PSEUDOMALLEI
    DANCE, DAB
    WUTHIEKANUN, V
    CHAOWAGUL, W
    SUPUTTAMONGKOL, Y
    WHITE, NJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 (02) : 321 - 324
  • [8] THE ANTIMICROBIAL SUSCEPTIBILITY OF PSEUDOMONAS-PSEUDOMALLEI - EMERGENCE OF RESISTANCE INVITRO AND DURING TREATMENT
    DANCE, DAB
    WUTHIEKANUN, V
    CHAOWAGUL, W
    WHITE, NJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (03) : 295 - 309
  • [9] OXA-16, a further extended-spectrum variant of OXA-10 β-lactamase, from two Pseudomonas aeruginosa isolates
    Danel, F
    Hall, LMC
    Gur, D
    Livermore, DM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) : 3117 - 3122
  • [10] OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain
    Danel, F
    Hall, LMC
    Gur, D
    Livermore, DM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) : 785 - 790